DIM
HRTX icon

DLK Investment Management’s Heron Therapeutics HRTX Stock Holding History

DLK Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14K Buy
44,710
+26,820
+150% +$10.2K 0.01% 97
2026
Q2 		$62.6K Buy
17,890
+6,200
+53% +$4.97K 0.03% 86
2026
Q1 		$9.35K Hold
11,690
– – ﹤0.01% 91
2025
Q4 		$15.2K Sell
11,690
-10,500
-47% -$13K 0.01% 87
2025
Q3 		$28K Buy
22,190
+4,800
+28% +$7.61K 0.01% 85
2025
Q2 		$36K Hold
17,390
– – 0.01% 82
2025
Q1 		$38.3K Hold
17,390
– – 0.02% 76
2024
Q4 		$26.6K Sell
17,390
-500
-3% -$810 0.01% 84
2024
Q3 		$35.6K Hold
17,890
– – 0.01% 102
2024
Q2 		$62.6K Hold
17,890
– – 0.03% 90
2024
Q1 		$49.6K Hold
17,890
– – 0.02% 92
2023
Q4 		$30.4K Buy
+17,890
New +$19.7K 0.01% 96

Other funds holding HRTX

AR
Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

DLK Investment Management's HRTX Position: Q3 2026 in Review

DLK Investment Management increased its Heron Therapeutics (HRTX) stake by 150% in Q3 2026, buying an estimated $10.2K and bringing the position to 44,710 shares worth $14K. The position accounts for 0.01% of the portfolio, ranked #97.

DLK Investment Management first reported a position in HRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $62.6K in Q2 2026. 5 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • DLK Investment Management held 44,710 shares of Heron Therapeutics worth $14K as of Q3 2026.
  • DLK Investment Management bought 26,820 Heron Therapeutics shares in Q3 2026, an estimated $10.2K.
  • Heron Therapeutics made up 0.01% of DLK Investment Management's portfolio in Q3 2026, its #97 holding.
  • DLK Investment Management first reported a position in Heron Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • DLK Investment Management's Heron Therapeutics position peaked at $62.6K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on DLK Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.